Inve India ▾

Sai Parenterals share price & results

Sai Parenterals Limited· Healthcare

Results to
Jun 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

Hyderabad pharma maker of branded generics and CDMO dosage forms/injectables; owns Noumed (Australia/NZ).

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue179 ₹ crore+435.1% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin13.2 %−1.0 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit7.9 ₹ crore+457.7% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equityUnavailable−11.9 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM · period unavailableNot in the analysed materials. No older figure is substituted.
Free cash flow margin7.09 %−18.7 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)Unavailable+127.9 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM · period unavailableNot in the analysed materials. No older figure is substituted.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

0 of 1 judged target kept · 11 open · verdicts reflect calls analysed to Q1 FY27.

Sai Parenterals Limited management guidance track record on Inve: 12 targets tracked across analysed earnings calls (0 achieved, 1 missed, 11 open).

TargetOriginal wordingSaidLatest callVerdict
Working Capital as % of Additional RevenueAbout 25% to 30% of additional revenues as the working capital requirement.
Call transcript, Q4 FY26 · 27 May 2026		Q4 FY26Q1 FY27:This guidance was not mentioned or updated in the Q1 FY27 earnings call.
Call transcript, Q1 FY27 · 12 Aug 2026		Ghosted
Noumed Australian Facility Operational StatusAustralian manufacturing facility becomes operational in Q4 FY '27
Call transcript, Q4 FY26 · 27 May 2026		Q4 FY26Q1 FY27:The timeline has been clarified: physical completion is targeted for January 2027, but Phase 1 manufacturing is now expected from April 2027, which is Q1 FY28. This marks a slight delay from the original 'operational in Q4 FY27' guidance.
Call transcript, Q1 FY27 · 12 Aug 2026		Delayed
FY27 Consolidated RevenueINR750 crores for the financial year '27
Call transcript, Q4 FY26 · 27 May 2026		Q4 FY26Q1 FY27:Management reiterated the full-year guidance of Rs. 750 crores in revenue for FY27. Q1 revenue of Rs. 182 crores represents 24% of the target, which management states is ahead of schedule given an expected 45:55 H1:H2 revenue split.
Call transcript, Q1 FY27 · 12 Aug 2026		On Track

Source: Inve Guidance Tracker for Sai Parenterals Limited · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

1 of Sai Parenterals Limited's 12 targets was missed. See which ones, and which are quietly gone. The 3 above are the free sample; 9 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹455.65 −1.31% · −₹6.05

Last close 26 Oct 2026 · NSE · INR · Source: Inve

Performance +12.3% YTD

₹400₹450₹500₹550₹600AprMayJunJulAugSeptOctQ4 FY26 — 27 May 2026Q1 FY27 — 12 Aug 2026

YTD: ₹405.7 on 2 Apr 2026 → ₹455.65. High ₹623.8 (2 Jul 2026), low ₹405.7 (2 Apr 2026).

Previous close
₹461.7
Market cap
₹2.0k Cr
52-week range
₹405.7 – ₹623.8
Price to earnings (FY ending Mar 2026)
143.79×
Return on equity (FY ending Mar 2026)
4.79%

Overview

Symbol
NSE:SAIPARENT
Exchange
NSE
Currency
INR

What Sai Parenterals Limited does

Based on the company's own presentations, annual report and earnings calls.

Sai Parenterals is a Hyderabad-headquartered pharmaceutical formulations company that develops, manufactures and exports branded generics and provides contract development and manufacturing (CDMO) services to regulated and semi-regulated markets. It operates four manufacturing units in Telangana focused on sterile injectables, cephalosporin and general oral dosage forms, plus a fifth unit, Revat Laboratories in Ongole, Andhra Pradesh, for domestic branded generics. In November 2025 it acquired a 74.6% stake in Australia's Noumed Pharmaceuticals, adding CDMO manufacturing and market access in Australia and New Zealand, with a new facility under construction in Adelaide. Revenue comes from domestic branded formulation sales and long-term CDMO supply contracts with customers in regulated export markets.

Segments

  • Branded Generic Formulations
  • CDMO (Contract Development & Manufacturing)
Manufacturing facilities
6 (Units I-IV in Telangana; Revat Laboratories in Ongole, Andhra Pradesh; Noumed facility under construction in Adelaide, Australia)
Product portfolio
302 complex products across critical therapeutic areas
Approved product registrations in regulated markets
599 (456 with TGA-Australia; 143 across other countries)
Product dossiers under development
67
Installed capacity - India injectable/oral-dosage units
Unit I: 42 million units/yr; Unit II: 15 million; Unit III: 240 million; Unit IV: 293 million
Installed capacity - Revat Laboratories (Ongole)
570 million units/year
Founded 2001Headquarters Hyderabad, Telangana, India

How the price took the results

close before → close after

Q1 FY27
−3.7%
12 Aug
Q4 FY26
+0.2%
27 May

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Sai Parenterals Limited

Free account: one company. Everything above stays public.

Write why you follow Sai Parenterals Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Sai Parenterals Limited

Guides on how to read this kind of business and the numbers that matter.